Innovation Pharmaceuticals Inc
Change company Symbol lookup
Select an option...
IPIX Innovation Pharmaceuticals Inc
LOTE Lot78 Inc
GIXEF Geologix Explorations Inc
GILXF Gitennes Exploration Inc
GIKLY Grifols SA
GIGNY Genting Singapore Ltd
GIGNF Genting Singapore Ltd
GIDYL GI Dynamics Inc
GHST Ghst International Inc
GHRI Goliath Resources Inc
Go

Health Care : Biotechnology | Company profile

Innovation Pharmaceuticals Inc., formerly Cellceutix Corporation, is a clinical-stage biopharmaceutical company. The Company is engaged in developing therapies with oncology, dermatology and antimicrobial applications. The Company owns the rights to various drug compounds, including Kevetrin (thioureidobutyronitrile), which is its anti-cancer compound; Prurisol (KM-133), which is in development for psoriasis, and Brilacidin, which is its drug in a class of compounds known as defensin-mimetics. The Company's clinical trials focus on evaluating its drug candidates, including Kevetrin for the treatment of cancers; Prurisol for the treatment of psoriasis, and Brilacidin for treatments of skin infections, prevention of oral mucositis complicating chemoradiation treatment for cancer, and ulcerative proctitis. The Company focuses on developing small molecule therapies to treat diseases in the areas of cancer, antibiotics and inflammatory disease.

Closing Price
$0.36
Day's Change
0.02 (5.88%)
Bid
--
Ask
--
B/A Size
--
Day's High
0.36
Day's Low
0.325
Volume
(Heavy Day)
Volume:
315,313

10-day average volume:
201,985
315,313
Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Copyright © 2018. All rights reserved.

Reuters content is the intellectual property of Reuters. Any copying, republication or redistribution of Reuters content, including by caching, framing or similar means, is expressly prohibited without the prior written consent of Reuters. Reuters is not liable for any errors or delays in content, or for any actions taken in reliance on any content. Reuters, Reuters Logo and the Sphere Logo are trademarks and registered trademarks of the Reuters Group of companies around the world.

Data is provided for information purposes only and is not intended for trading purposes. Reuters shall not be liable for any errors or delay in the content, or for any action taken in reliance on any content. The RIC or Reuters Instrument Code set has been developed and maintained by Reuters and is the intellectual property of Reuters.